ACAD - ACADIA Pharmaceuticals Inc.
| Previous Close | 17.93 |
| Open | 17.79 |
| Bid | 17.67 x 800 |
| Ask | 18.20 x 3200 |
| Day's Range | 17.56 - 18.27 |
| 52 Week Range | 12.77 - 32.99 |
| Volume | 1,160,432 |
| Avg. Volume | 3,014,590 |
| Market Cap | 2.538B |
| Beta (3Y Monthly) | 3.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings Date | Feb 25, 2019 - Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.36 |
- Simply Wall St.•2 days ago
Why ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Could Be Your Next Investment
I've been keeping an eye on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) because I'm attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believe Read More...
Markit•11 days agoSee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD
- GlobeNewswire•12 days ago
Analysis: Positioning to Benefit within Symantec, ACADIA Pharmaceuticals, Novavax, BBX Capital, Paychex, and US Foods Holding — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•15 days ago
ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced the closing of its previously announced underwritten public offering of 18,602,941 shares of its common stock, including 2,426,470 shares of common stock sold pursuant to the underwriters’ ...
Market Realist•16 days agoWhy Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
On November 28, Acadia Pharmaceuticals (ACAD) stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27. On November 27, Acadia Pharmaceuticals announced a price of $17.00 per share for an underwritten public offering of 16,176,471 shares of its common stock. Acadia Pharmaceuticals’ net revenue in the first nine months of the year amounted to $164.2 million compared to $81.3 million in the same period last year.
- Motley Fool•17 days ago
Here's Why Acadia Pharmaceuticals Is Soaring
Shares rebound after the company announces the pricing details of its common stock offering.
- ACCESSWIRE•17 days ago
Today’s Research Reports on Stocks to Watch: Loxo Oncology and ACADIA Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 28, 2018 / Loxo Oncology and ACADIA Pharmaceuticals were two biotech stocks sinking on Tuesday. Traders showed their concern over ACADIA pricing a public offering of ...
- Business Wire•18 days ago
ACADIA Pharmaceuticals Prices Public Offering of Common Stock
ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 16,176,471 shares of its common stock, offered at a price to the public of $17.00 per share. The gross proceeds from this offering to ACADIA are expected to be approximately $275.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchase up to an aggregate of 2,426,470 additional shares of common stock.
Markit•18 days agoSee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD
- Benzinga•18 days ago
The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 26) Emergent Biosolutions Inc (NYSE: EBS ) Vericel Corp ...
- ACCESSWIRE•18 days ago
Today's Research Reports on Trending Tickers: Novavax and ACADIA Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 27, 2018 / Wall Street closed up on Monday as oil prices stabilized and giant tech stocks such as the FAANG (Facebook, Amazon, Apple, Netflix and Google-parent Alphabet), ...
- Business Wire•19 days ago
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $200,000,000 of its common stock. BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as the joint book-running managers for the offering. ACADIA intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of its common stock.
Market Realist•19 days agoA Look at Amarin Corporation’s Stock Performance Year-to-Date
Amarin stock rose from $2.35 at the close of market on December 29, 2017, to $18.97 at the close of market on November 21, 2018, reflecting a ~449% year-to-date rise. Amarin hit its 52-week high of $23.34 on November 6. Amarin’s net revenue in the first nine months of 2018 amounted to $151.9 million compared to $127.2 million in the same period of the previous year, reflecting a ~19% YoY (year-over-year) rise.
Markit•21 days agoSee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD
- Thomson Reuters StreetEvents•last month
Edited Transcript of ACAD earnings conference call or presentation 6-Nov-18 10:00pm GMT
Q3 2018 ACADIA Pharmaceuticals Inc Earnings Call
- Simply Wall St.•last month
Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc’s (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Read More...
Markit•last monthSee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD
- Zacks•last month
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of 13.79% and 0.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Acadia: 3Q Earnings Snapshot
The San Diego-based company said it had a loss of 50 cents per share. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a ...
- Business Wire•last month
ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results
-Third Quarter Net Sales Grew to $58.3 Million
Market Realist•last monthHow Wall Street Analysts View Exelixis
Exelixis (EXEL) reported net income of $126.6 million in the third quarter compared to $81.4 million in the third quarter of 2017. The company’s net income over the first nine months of this year amounted to $330.0 million compared to $115.7 million in the same period the prior year.
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and ACADIA Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Shares of Tonix Pharmaceuticals were flying higher in Wednesday’s session on news that the company plans to start a new Phase 3 trial of Tonmya, a drug formulation ...
Markit•last monthSee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD
- Business Wire•2 months ago
ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD)
ACADIA Pharmaceuticals Inc. (ACAD) today announced positive top-line results from CLARITY, a randomized, double-blind, placebo-controlled, multi-center, sequential parallel comparison design (SPCD) study in major depressive disorder (MDD). In the study, 207 adult patients with a confirmed inadequate response to existing first-line SSRI or SNRI therapy for MDD received adjunctive treatment of either 34 mg pimavanserin or placebo in addition to pre-existing first-line therapy for five weeks (Stage 1).
- Zacks•2 months ago
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
